<p>Immunome, Inc.（纳斯达克代码：IMNM - 获取免费报告）周三股价上涨 6.3%。该股票最高交易价为 9.65 美元，最后交易价为 9.86 美元。交易期间约有 33,020 股被交易，较 982,897 股的日均交易量下降了 97%。该股票此前收盘价为 9.28 美元。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>3 只小型股具有巨大的增长潜力</li>
</ul>
<p>几位股票分析师最近对 IMNM 股票进行了评估。Wedbush 在 8 月 7 日的研究报告中重申了 “跑赢大盘” 的评级，并将 Immunome 的目标股价设定为 21.00 美元。Evercore ISI 在 8 月 22 日的研究报告中开始覆盖 Immunome 的股票。他们为该公司设定了 “跑赢大盘” 的评级和 18.00 美元的目标价。摩根大通在 8 月 7 日的研究报告中将 Immunome 的目标价从 23.00 美元下调至 22.00 美元，并为该公司设定了 “增持” 的评级。Wall Street Zen 在 5 月 22 日的研究报告中将 Immunome 的评级从 “卖出” 上调至 “持有”。最后，Guggenheim 在 8 月 25 日的研究报告中重申了 “买入” 评级，并将 Immunome 的目标股价设定为 25.00 美元。根据 MarketBeat 的数据，八位股票研究分析师对该股票给予了 “买入” 评级，Immunome 的共识评级为 “买入”，平均目标价为 22.50 美元。</p>
<p><strong>查看我们最新的 IMNM 股票报告</strong></p>
<h2>Immunome 股票表现</h2>
<p>该股票市值为 8.59 亿美元，市盈率为-3.20，贝塔值为 1.92。该公司的 50 日移动平均价格为 9.80 美元，200 日移动平均价格为 8.84 美元。</p>
<p>Immunome（纳斯达克代码：IMNM - 获取免费报告）最近在 8 月 6 日发布了季度财报。该公司报告季度每股收益为（0.50 美元），超出市场共识预期的（0.52 美元）0.02 美元。该公司季度收入为 402 万美元，而市场共识预期为 103 万美元。Immunome 的净利润率为-1,687.08%，股本回报率为-76.10%。分析师预计 Immunome, Inc.在当前财政年度的每股收益为-2.21 美元。</p>
<h2>机构资金流入和流出</h2>
<p>一些机构投资者最近增加或减少了对该公司的持股。Tower Research Capital LLC TRC 在第二季度将其在 Immunome 的持股增加了 121.2%。Tower Research Capital LLC TRC 现在拥有 6,938 股该公司的股票，价值 65,000 美元，此前在该期间购买了 3,802 股。法国巴黎银行金融市场在第二季度将其在 Immunome 的持股增加了 81.8%。法国巴黎银行金融市场现在拥有 6,464 股该公司的股票，价值 60,000 美元，此前在该期间购买了 2,909 股。Birchview Capital LP 在第二季度购买了 Immunome 的新头寸，价值约 558,000 美元。Balyasny Asset Management L.P.在第二季度购买了 Immunome 的新头寸，价值约 1,021,000 美元。最后，制造商人寿保险公司在第二季度将其在 Immunome 的持股增加了 3.6%。制造商人寿保险公司现在拥有 280,816 股该公司的股票，价值 2,612,000 美元，此前在该期间购买了 9,686 股。对冲基金和其他机构投资者持有该公司 44.58% 的股份。</p>
<h2>关于 Immunome</h2>
<p>（获取免费报告）</p>
<p>Immunome, Inc.是一家生物技术公司，开发靶向癌症疗法。该公司的临床资产包括 AL102，一种正在评估的伽马分泌酶抑制剂，目前正在进行针对纤维瘤的三期临床试验；前临床资产包括 IM-1021，一种受体酪氨酸激酶样孤儿受体 1 和抗体药物偶联物，以及 IM-3050，一种靶向成纤维细胞活化蛋白的放射性配体疗法；以及 IM-4320，一种抗 IL-38 免疫疗法候选药物。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票超过 Immunome</li>
<li>如何做空纳斯达克：简单易懂的指南</li>
<li>IREN 因 AI 转型而上涨 186%——而且这才刚刚开始</li>
<li>3 只国防股票将受益于军事支出增加</li>
<li>火箭实验室通过新发射台加强突破的案例</li>
<li>资产配置：成功投资组合的关键。你在关注自己的投资组合吗？</li>
<li>Opera Limited 股票预计将在 2025 年以高点结束</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Immunome 吗？</h2>
<p>在考虑 Immunome 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Immunome 并不在名单上。</p>
<p>虽然 Immunome 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IMNM

<p>Immunome（纳斯达克代码：IMNM）股价上涨 6.3%，至 9.86 美元，尽管交易量显著下降。分析师维持一致的 “买入” 评级，平均目标价为 22.50 美元。该公司报告的季度每股收益为（0.50 美元），超出预期，收入为 402 万美元。机构投资者持有该股票的 44.58%，Immunome 专注于开发靶向癌症疗法，包括用于纤维瘤的 AL102。最近的分析师评级包括 Wedbush 的目标价 21.00 美元和 Guggenheim 的目标价 25.00 美元</p>

<p>Immunome, Inc. (NASDAQ:IMNM - Get Free Report) shares were up 6.3% on Wednesday . The stock traded as high as $9.65 and last traded at $9.86. Approximately 33,020 shares were traded during trading, a decline of 97% from the average daily volume of 982,897 shares. The stock had previously closed at $9.28.</p>
<div class="lb-trans"><p>Immunome, Inc.（纳斯达克代码：IMNM - 获取免费报告）周三股价上涨 6.3%。该股票最高交易价为 9.65 美元，最后交易价为 9.86 美元。交易期间约有 33,020 股被交易，较 982,897 股的日均交易量下降了 97%。该股票此前收盘价为 9.28 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>3 Small-Cap Stocks With Big Growth Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小型股具有巨大的增长潜力</li>
</ul>
</div><p>Several equities analysts recently weighed in on IMNM shares. Wedbush reaffirmed an &#34;outperform&#34; rating and set a $21.00 target price on shares of Immunome in a research note on Thursday, August 7th. Evercore ISI started coverage on shares of Immunome in a research report on Friday, August 22nd. They set an &#34;outperform&#34; rating and a $18.00 price objective for the company. JPMorgan Chase &amp; Co. lowered their price objective on shares of Immunome from $23.00 to $22.00 and set an &#34;overweight&#34; rating for the company in a research report on Thursday, August 7th. Wall Street Zen upgraded shares of Immunome from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, May 22nd. Finally, Guggenheim reiterated a &#34;buy&#34; rating and set a $25.00 price objective on shares of Immunome in a research report on Monday, August 25th. Eight equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Immunome has a consensus rating of &#34;Buy&#34; and an average price target of $22.50.</p>
<div class="lb-trans"><p>几位股票分析师最近对 IMNM 股票进行了评估。Wedbush 在 8 月 7 日的研究报告中重申了 “跑赢大盘” 的评级，并将 Immunome 的目标股价设定为 21.00 美元。Evercore ISI 在 8 月 22 日的研究报告中开始覆盖 Immunome 的股票。他们为该公司设定了 “跑赢大盘” 的评级和 18.00 美元的目标价。摩根大通在 8 月 7 日的研究报告中将 Immunome 的目标价从 23.00 美元下调至 22.00 美元，并为该公司设定了 “增持” 的评级。Wall Street Zen 在 5 月 22 日的研究报告中将 Immunome 的评级从 “卖出” 上调至 “持有”。最后，Guggenheim 在 8 月 25 日的研究报告中重申了 “买入” 评级，并将 Immunome 的目标股价设定为 25.00 美元。根据 MarketBeat 的数据，八位股票研究分析师对该股票给予了 “买入” 评级，Immunome 的共识评级为 “买入”，平均目标价为 22.50 美元。</p>
</div><p><strong>View Our Latest Stock Report on IMNM</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 IMNM 股票报告</strong></p>
</div><h2>Immunome Stock Performance</h2>
<div class="lb-trans"><h2>Immunome 股票表现</h2>
</div><p>The stock has a market cap of $859.00 million, a P/E ratio of -3.20 and a beta of 1.92. The company's fifty day moving average price is $9.80 and its 200-day moving average price is $8.84.</p>
<div class="lb-trans"><p>该股票市值为 8.59 亿美元，市盈率为-3.20，贝塔值为 1.92。该公司的 50 日移动平均价格为 9.80 美元，200 日移动平均价格为 8.84 美元。</p>
</div><p>Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.02. The company had revenue of $4.02 million for the quarter, compared to the consensus estimate of $1.03 million. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. Analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Immunome（纳斯达克代码：IMNM - 获取免费报告）最近在 8 月 6 日发布了季度财报。该公司报告季度每股收益为（0.50 美元），超出市场共识预期的（0.52 美元）0.02 美元。该公司季度收入为 402 万美元，而市场共识预期为 103 万美元。Immunome 的净利润率为-1,687.08%，股本回报率为-76.10%。分析师预计 Immunome, Inc.在当前财政年度的每股收益为-2.21 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its position in Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock valued at $65,000 after purchasing an additional 3,802 shares during the period. BNP Paribas Financial Markets increased its position in Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock valued at $60,000 after purchasing an additional 2,909 shares during the period. Birchview Capital LP purchased a new position in Immunome during the 2nd quarter valued at about $558,000. Balyasny Asset Management L.P. purchased a new position in Immunome during the 2nd quarter valued at about $1,021,000. Finally, The Manufacturers Life Insurance Company increased its position in Immunome by 3.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company's stock valued at $2,612,000 after purchasing an additional 9,686 shares during the period. Hedge funds and other institutional investors own 44.58% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了对该公司的持股。Tower Research Capital LLC TRC 在第二季度将其在 Immunome 的持股增加了 121.2%。Tower Research Capital LLC TRC 现在拥有 6,938 股该公司的股票，价值 65,000 美元，此前在该期间购买了 3,802 股。法国巴黎银行金融市场在第二季度将其在 Immunome 的持股增加了 81.8%。法国巴黎银行金融市场现在拥有 6,464 股该公司的股票，价值 60,000 美元，此前在该期间购买了 2,909 股。Birchview Capital LP 在第二季度购买了 Immunome 的新头寸，价值约 558,000 美元。Balyasny Asset Management L.P.在第二季度购买了 Immunome 的新头寸，价值约 1,021,000 美元。最后，制造商人寿保险公司在第二季度将其在 Immunome 的持股增加了 3.6%。制造商人寿保险公司现在拥有 280,816 股该公司的股票，价值 2,612,000 美元，此前在该期间购买了 9,686 股。对冲基金和其他机构投资者持有该公司 44.58% 的股份。</p>
</div><h2>About Immunome</h2>
<div class="lb-trans"><h2>关于 Immunome</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.</p>
<div class="lb-trans"><p>Immunome, Inc.是一家生物技术公司，开发靶向癌症疗法。该公司的临床资产包括 AL102，一种正在评估的伽马分泌酶抑制剂，目前正在进行针对纤维瘤的三期临床试验；前临床资产包括 IM-1021，一种受体酪氨酸激酶样孤儿受体 1 和抗体药物偶联物，以及 IM-3050，一种靶向成纤维细胞活化蛋白的放射性配体疗法；以及 IM-4320，一种抗 IL-38 免疫疗法候选药物。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Immunome</li>
<li>How to Short Nasdaq: An Easy-to-Follow Guide</li>
<li>IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started</li>
<li>3 Defense Stocks Set to Benefit From Increased Military Spending</li>
<li>Rocket Lab Strengthens Case for Breakout With New Launch Pad</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Opera Limited Stock Set to End 2025 on a High Note</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Immunome</li>
<li>如何做空纳斯达克：简单易懂的指南</li>
<li>IREN 因 AI 转型而上涨 186%——而且这才刚刚开始</li>
<li>3 只国防股票将受益于军事支出增加</li>
<li>火箭实验室通过新发射台加强突破的案例</li>
<li>资产配置：成功投资组合的关键。你在关注自己的投资组合吗？</li>
<li>Opera Limited 股票预计将在 2025 年以高点结束</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunome Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Immunome 吗？</h2>
</div><p>Before you consider Immunome, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Immunome 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Immunome 并不在名单上。</p>
</div><p>While Immunome currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Immunome 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Immunome（纳斯达克股票代码：IMNM）股价上涨 6.3% - 是否仍然值得购买？